go-v.orgdoi

Pertuzumab: a step forward in treating HER2-positive breast cancer

Dimitriοs Mavroudis · Translational Cancer Research · 2012

  • DOI 10.21037/377
  • Publisher AME Publishing Company
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Translational Cancer Research · AME Publishing Company · article · 2012

Abstract

HER2-positive breast cancer represents an aggressive subtype of the disease occurring in approximately 20% of patients. While trastuzumab has revolutionized the treatment of HER2-positive breast cancer, a proportion of patients have de novo trastuzumab-resistant disease and even those who initially respond will eventually develop trastuzumab-resistance. The recent publication in the New England Journal of Medicine of the promising results of the CLEOPATRA trial for the combination of pertuzumab plus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer (MBC) represented a significant advancement in the treatment of this illness (1).

Open the resolved locator · 10.21037/377

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 17:29 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://tcr.amegroups.com/article/viewFile/377/843
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.